Exane Derivatives’s Phillips 66 PSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$820 Hold
10
﹤0.01% 526
2022
Q1
$864 Hold
10
﹤0.01% 812
2021
Q4
$725 Hold
10
﹤0.01% 737
2021
Q3
$700 Hold
10
﹤0.01% 903
2021
Q2
$817 Hold
10
﹤0.01% 896
2021
Q1
$815 Sell
10
-1,244
-99% -$97.6K ﹤0.01% 753
2020
Q4
$87.7K Buy
+1,254
New +$73.6K 0.03% 410
2020
Q2
Sell
-670
Closed -$35.9K 736
2020
Q1
$35.9K Sell
670
-37,206
-98% -$3.03M 0.01% 381
2019
Q4
$3.97M Buy
37,876
+4,795
+14% +$539K 0.74% 34
2019
Q3
$3.39M Sell
33,081
-6,468
-16% -$648K 0.61% 44
2019
Q2
$3.7M Buy
39,549
+1,305
+3% +$117K 0.65% 40
2019
Q1
$3.64M Buy
+38,244
New +$3.64M 0.72% 49
2016
Q2
Sell
-128
Closed -$11.1K 611
2016
Q1
$11.1K Sell
128
-57
-31% -$4.63K ﹤0.01% 410
2015
Q4
$15.1K Hold
185
﹤0.01% 306
2015
Q3
$14.2K Sell
185
-3,085
-94% -$245K ﹤0.01% 331
2015
Q2
$263K Buy
3,270
+627
+24% +$49.8K 0.03% 187
2015
Q1
$208K Sell
2,643
-2,598
-50% -$191K 0.02% 203
2014
Q4
$376K Buy
+5,241
New +$387K 0.05% 160

Other funds holding PSX

Exane Derivatives's PSX Position: Q2 2022 in Review

Exane Derivatives held its Phillips 66 (PSX) position steady in Q2 2022 at 10 shares worth $820. The position accounts for ﹤0.01% of the portfolio, ranked #526.

Exane Derivatives first reported a position in PSX in Q4 2014 and has held it in 18 quarters since. The position peaked at $3.97M in Q4 2019. 1,444 funds tracked by Wall St. Rank hold PSX as of Q2 2022.

  • Exane Derivatives held 10 shares of Phillips 66 worth $820 as of Q2 2022.
  • Exane Derivatives left its Phillips 66 share count unchanged in Q2 2022.
  • Phillips 66 made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #526 holding.
  • Exane Derivatives first reported a position in Phillips 66 in Q4 2014 and has held it in 18 quarters since.
  • Exane Derivatives's Phillips 66 position peaked at $3.97M in Q4 2019.
  • 1,444 funds tracked by Wall St. Rank held Phillips 66 as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.